0930 GMT - DSM-Firmenich could launch another share buyback program in 2026, analysts at Equita write. This follows the nutrition, health and bioscience company announcing a surprise 1 billion euro buyback alongside its fourth-quarter results. The buyback launched on Thursday will be executed over the next 12 months and is valued at 3.7% of its market capitalization, they write. The buyback follows solid fourth-quarter results, which were slightly better than expected, the analysts write. Shares trade up 2.62% at 103.65 euros. (adam.whittaker@wsj.com)
(END) Dow Jones Newswires
February 13, 2025 04:31 ET (09:31 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.